Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts
US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector.
Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare research Jialin Zhang, in a research note on Sunday.
The US Treasury Department was drafting investment...
此摘要由5News从媒体的公开信息源汇聚而成。 包含完整背景的全文在www.scmp.com — 内容归South China Morning Post - Business所有。
